GlassScriptPhysician profile
Dana L Nickell
NPI 1871794990
$3,726.80
in general payments reported to CMS, 2019-2025
23 companies · $22.26 in 2025
The $22.26 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $633 · 2022: $1,192 · 2023: $1,361 · 2024: $518 · 2025: $22.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.64 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,470.79 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $486.97 | 2021-2025 | Relistor |
| Pfizer INC. | $226.31 | 2023-2024 | |
| Currax Pharmaceuticals LLC | $208.88 | 2021-2024 | Contrave, Onzetra Xsail, Nexletol |
| Scilex Pharmaceuticals INC. | $173.26 | 2022-2024 | Ztlido |
| Collegium Pharmaceutical, INC. | $170.17 | 2021-2023 | Xtampza, Belbuca |
| Ibsa Pharma INC. | $156.78 | 2021-2023 | Tirosint, Licart |
| Hikma Pharmaceuticals USA | $146.99 | 2022 | |
| Lilly USA, LLC | $110.04 | 2021-2022 | |
| Abbott Laboratories | $107.65 | 2021 | |
| Azurity Pharmaceuticals, INC. | $73.72 | 2023-2024 | Horizant, Horizant |
| Teva Pharmaceuticals USA, INC. | $71.58 | 2022-2023 | Ajovy, Austedo |
| Amgen INC. | $61.66 | 2021-2022 | |
| Allergan, INC. | $56.40 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.42 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $35.96 | 2021 | |
| Boston Scientific Corporation | $27.01 | 2023 | Wavewriter Alpha Prime 16 |
| Kowa Pharmaceuticals America, INC. | $19.27 | 2023 | Seglentis |
| Biodelivery Sciences International, INC. | $16.76 | 2021 | |
| Eisai INC. | $15.71 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.31 | 2021 | |
| Grt US Holding, INC. | $14.04 | 2022 | |
| Ferring Pharmaceuticals INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Nickell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.